These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 11776324

  • 1. The ability of poloxamers to inhibit platelet aggregation depends on their physicochemical properties.
    Ahmed F, Alexandridis P, Shankaran H, Neelamegham S.
    Thromb Haemost; 2001 Dec; 86(6):1532-9. PubMed ID: 11776324
    [Abstract] [Full Text] [Related]

  • 2. Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists.
    Malovichko OL, Petrus AS, Krysko AA, Kabanova TA, Andronati SA, Karaseva TL, Kiriyak AV.
    Bioorg Med Chem Lett; 2006 Oct 15; 16(20):5294-7. PubMed ID: 16919941
    [Abstract] [Full Text] [Related]

  • 3. Changes in platelet response to adenosine 5'-diphosphate caused by verapamil.
    Walkowiak B, Koziołkiewicz W, Michalec L, Pawłowska Z, Krzesłowska J, Cierniewski CS.
    Pol J Pharmacol; 1996 Oct 15; 48(3):303-5. PubMed ID: 9112667
    [Abstract] [Full Text] [Related]

  • 4. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M, Tomasiak M, Rusak T, Winnicka K, Dobrzycki S.
    Blood Coagul Fibrinolysis; 2008 Sep 15; 19(6):557-67. PubMed ID: 18685439
    [Abstract] [Full Text] [Related]

  • 5. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY, Wu YC, Wu CC.
    Mol Pharmacol; 2006 Oct 15; 70(4):1380-9. PubMed ID: 16837624
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and biological evaluation of PEG-tirofiban conjugates.
    Désaubry L, Riché S, Laeuffer P, Cazenave JP.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2028-31. PubMed ID: 18304813
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
    Mousa SA, Ahmad S.
    Am J Hematol; 2007 Apr 15; 82(4):276-82. PubMed ID: 17039513
    [Abstract] [Full Text] [Related]

  • 9. Allicin and disulfiram enhance platelet integrin alphaIIbbeta3-fibrinogen binding.
    Manaster Y, Shenkman B, Rosenberg N, Savion N.
    Thromb Res; 2009 Sep 15; 124(4):477-82. PubMed ID: 19632706
    [Abstract] [Full Text] [Related]

  • 10. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV, Khaspekova SG, Zabotina AM, Shimanova YV, Mazurov AV.
    Platelets; 2007 Nov 15; 18(7):506-14. PubMed ID: 17957566
    [Abstract] [Full Text] [Related]

  • 11. Formation of viscoelastic protein layers on polymeric surfaces relevant to platelet adhesion.
    Weber N, Wendel HP, Kohn J.
    J Biomed Mater Res A; 2005 Mar 15; 72(4):420-7. PubMed ID: 15678483
    [Abstract] [Full Text] [Related]

  • 12. The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation.
    Jagroop IA, Mikhailidis DP.
    Clin Appl Thromb Hemost; 2008 Jul 15; 14(3):295-302. PubMed ID: 18445610
    [Abstract] [Full Text] [Related]

  • 13. A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro.
    Marques JA, George JK, Smith IJ, Bhakta V, Sheffield WP.
    Thromb Haemost; 2001 Sep 15; 86(3):902-8. PubMed ID: 11583325
    [Abstract] [Full Text] [Related]

  • 14. Interactions of platelets with Synthocytes, a novel platelet substitute.
    Davies AR, Judge HM, May JA, Glenn JR, Heptinstall S.
    Platelets; 2002 Jun 15; 13(4):197-205. PubMed ID: 12189020
    [Abstract] [Full Text] [Related]

  • 15. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
    Straub A, Wendel HP, Dietz K, Schiebold D, Peter K, Schoenwaelder SM, Ziemer G.
    Thromb Haemost; 2008 Mar 15; 99(3):609-15. PubMed ID: 18327411
    [Abstract] [Full Text] [Related]

  • 16. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O'connor CM.
    Am Heart J; 2003 Oct 15; 146(4):713-20. PubMed ID: 14564328
    [Abstract] [Full Text] [Related]

  • 17. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.
    Tsikaris V.
    J Pept Sci; 2004 Oct 15; 10(10):589-602. PubMed ID: 15526708
    [Abstract] [Full Text] [Related]

  • 18. Purification and characterization of a new platelet aggregation inhibitor with dissociative effect on ADP-induced platelet aggregation, from the venom of Protobothrops elegans (Sakishima-habu).
    Oyama E, Furudate N, Senuki K, Takahashi H.
    Toxicon; 2009 Jun 15; 53(7-8):706-12. PubMed ID: 19254737
    [Abstract] [Full Text] [Related]

  • 19. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM, Reininger AJ, Toth O, Deckmyn H, Brandl R, Siess W.
    Thromb Haemost; 2007 Mar 15; 97(3):435-43. PubMed ID: 17334511
    [Abstract] [Full Text] [Related]

  • 20. Platelet pro-aggregatory effects of CD40L monoclonal antibody.
    Mirabet M, Barrabés JA, Quiroga A, Garcia-Dorado D.
    Mol Immunol; 2008 Feb 15; 45(4):937-44. PubMed ID: 17959249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.